Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium
Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))))), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent will be presented as a poster at the 2024 AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), to be held in Barcelona, Spain (October 23-25, 2024). The patients were enrolled in the biomarker-enriched, Cohort 8 of the proof of concept study and were preselected for CDKN2A and/or CDKN2B abnormalities.
Cyclacel Pharmaceuticals, Inc. (納斯達克:CYCC, 納斯達克:CYCCP, Cyclacel, 或公司), 一家開發創新癌症藥物的生物製藥公司, 今天宣佈, 來自參加fadraciclib單藥物作爲單藥物進行的第2階段065-101臨床研究中12名患有晚期固體瘤的病人的初步安全性和有效性數據將被作爲海報展示在2024年AACR-新華保險-EORTC第36屆分子靶點和癌症治療研討會(「三重會議」)上，該會議將於2024年10月23日至25日在西班牙巴塞羅那舉行。這些患者是超過概念研究中生物標誌富集的第8隊列中的受試者, 並且已經預先選擇了CDKN2A和/或CDKN20億異常。
Details of the presentation are listed below:
以下是演講的詳細內容:
| Title: | Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations |
| Abstract Number: | 59 |
| Session: | Molecular Targeted Agents |
| Date/Time: | 12:00 p.m. – 7:00 p.m. CEST on Wednesday, October 23, 2024 |
| 標題： | Fadraciclib是一種口服CDK2/9抑制劑，在患有CDKN2A和/或CDKN20億基因改變的患者中，該患者患有晚期實體瘤和淋巴瘤 |
| 摘要編號： | 59 |
| 會議主題： | 分子靶向藥物 |
| 日期/時間: | 2024年10月23日（星期三）下午12:00至下午7:00中歐夏令時間 |
譯文內容由第三人軟體翻譯。
